| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3087 |
| Trial ID | NCT05432635 |
| Disease | Mantle Cell Lymphoma | B-Cell Non-Hodgkin's Lymphoma | Diffuse Large B-Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Co-treatment | CMV-MVA Triplex |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma |
| Year | 2022 |
| Country | United States |
| Company sponsor | City of Hope Medical Center |
| Other ID(s) | 20695|NCI-2022-04622|20695|P30CA033572|P50CA107399 |
| Cohort 1 | |||||||
|
|||||||